Skip to main navigation
  • mail icon
  • fb icon
  • linkedin icon

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
    • Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use
  • mail icon
  • fb icon
  • linkedin icon

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
    • Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use

Investors

Press Releases

Date
Latest Press Release

December 19, 2018

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies

December 18, 2018

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection

December 17, 2018

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection

December 11, 2018

Eiger BioPharmaceuticals Reports on 2018 R&D Day

December 4, 2018

Eiger BioPharmaceuticals to Host R&D Day in New York City

December 3, 2018

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer

December 3, 2018

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies

November 19, 2018

Eiger to Participate in Piper Jaffray Healthcare Conference

November 9, 2018

Eiger Bio Reports Third Quarter 2018 Financial Results

October 23, 2018

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Next page next ›
  • Last page last »

Eiger - Shareholder Tools

  • Print Page
  • Contact Us
  • RSS Feeds
  • Email Alerts
  • IR Contacts

Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX

Contact Us

Eiger Logo

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX